Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Efficacy data from Escalón study shows improvements in central corneal thickness and best corrected visual acuity

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held May 5-8, 2023 in San Diego, California.

At Eyecelerator and ASCRS 2023, data will be presented from the Company’s Escalón study, which treated subjects with its novel cell therapy, AURN001. In this study, 22 subjects diagnosed with corneal edema secondary to corneal endothelial disease were treated intracamerally with a consistent dose of endothelial cells and three different doses of Y-27632, a rho kinase inhibitor.

“We are thrilled to share Escalón findings in multiple sessions at the ASCRS 2023 and Eyecelerator meetings,” said Michael Goldstein, president and chief medical officer, Aurion Biotech. “Escalón data are consistent with our previous trials showing clinically meaningful improvements in central corneal thickness and best corrected visual acuity. We believe these presentations will be of significant interest to the ophthalmology community and will help to highlight the exciting potential of AURN001 to treat patients with corneal endothelial disease.”

The schedule of corporate presentations is as follows:

  • Transformational Cell Therapy for Corneal Endothelial Disease
    • Thursday, May 4, 2023
    • 1:00 p.m. – 2:30 p.m. PDT
    • Eyecelerator, Marriott Marquis San Diego Marina
    • Presenter: Michael Goldstein, President and Chief Medical Officer, Aurion Biotech
  • If Not First, You’re Last: First-in-Human Studies
    • Thursday, May 4, 2023
    • 3:45 p.m. - 4:15 p.m. PDT
    • Eyecelerator, Marriott Marquis San Diego Marina
    • Panelist: Greg Kunst, Chief Executive Officer, Aurion Biotech

Aurion Biotech and its cell therapy will also be mentioned in the following ASCRS scientific presentations:

Aurion Biotech’s combination therapy recently received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), for the treatment of bullous keratopathy, marking the first-ever regulatory approval in the world for an allogeneic cell therapy to treat corneal endothelial disease.

About Aurion Biotech

With offices in Seattle, Cambridge and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company’s first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more about Aurion Biotech, visit www.aurionbiotech.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005700/en/

Contacts

Judith McGarry
(corporate communications)
415-971-2900
judith.mcgarry@aurionbiotech.com

Michele Gray
(ophthalmology media)
917-449-9250
michele@mgraycommunications.com

Beth Keshishian
(biotech & business media)
917-912-7195
beth@bethkeshishian.com

Source: Aurion Biotech

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20230502005700/en

Back to news